Manufacturer of Controlled Substances Registration: PCAS-Nanosyn, LLC, 54327-54328 [2015-22626]
Download as PDF
<![CDATA[
54327
Federal Register / Vol. 80, No. 174 / Wednesday, September 9, 2015 / Notices
21 CFR 1301.43 on or before October 9,
2015.
Written comments should be
sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152. Comments
and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
ADDRESS:
The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section. 7
of 28 CFR part 0, appendix to subpart
R.
In accordance with 21 CFR
1301.34(a), this is notice that on July 22,
2015, Chattem Chemicals, Inc., 3801 St.
Elmo Avenue, Chattanooga, Tennessee
37409 applied to be registered as an
importer of the following basic classes
of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Schedule
Lhorne on DSK5TPTVN1PROD with NOTICES
Methamphetamine (1105) ............
4-Anilino-N-phenethyl-4-piperidine
(8333).
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
II
II
II
II
II
II
The company plans to import the
listed controlled substances to bulk
manufacture other controlled substances
for distribution to its customers. The
company plans to import an
intermediate form of tapentadol (9780),
to bulk manufacturer tapentadol (9780)
for distribution to its customers. The
company plans to import Phenylacetone
(8501) in bulk for the manufacture of a
controlled substance.
VerDate Sep<11>2014
14:19 Sep 08, 2015
Jkt 235001
Dated: September 1, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
Dated: September 1, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–22624 Filed 9–8–15; 8:45 am]
[FR Doc. 2015–22625 Filed 9–8–15; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Akorn, Inc.
Manufacturer of Controlled
Substances Registration: PCASNanosyn, LLC
ACTION:
Notice of application.
ACTION:
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.34(a) on or before
October 9, 2015. Such persons may also
file a written request for a hearing on
the application pursuant to 21 CFR
1301.43 on or before October 9, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on May 14,
2015, Akorn, Inc., 1222 W. Grand
Avenue, Decatur, Illinois 62522 applied
to be registered as an importer of
remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
remifentanil in dosage form for
distribution.
DATES:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Notice of registration.
PCAS-Nanosyn, LLC applied
to be registered as a manufacturer of
certain basic classes of controlled
substances. The Drug Enforcement
Administration (DEA) grants PCASNanosyn, LLC registration as a
manufacturer of those controlled
substances.
SUMMARY:
SUPPLEMENTARY INFORMATION:
By notice dated May 15, 2015, and
published in the Federal Register on
May 21, 2015, 80 FR 29336, PCASNanosyn, LLC, 3331–B Industrial Drive,
Santa Rosa, California 95403 applied to
be registered as a manufacturer of
certain basic classes of controlled
substances. No comments or objections
were submitted for this notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of PCAS-Nanosyn, LLC
to manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances:
Controlled substance
Oxycodone (9143) ........................
Oripavine (9330) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufacturers
E:\FR\FM\09SEN1.SGM
09SEN1
54328
Federal Register / Vol. 80, No. 174 / Wednesday, September 9, 2015 / Notices
derivatives of controlled substances in
bulk form.
Dated: September 1, 2015
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–22626 Filed 9–8–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
Lhorne on DSK5TPTVN1PROD with NOTICES
178th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of
Teleconference Meeting
Pursuant to the authority contained in
Section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 178th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans (also
known as the ERISA Advisory Council)
will be held as a teleconference on
September 30, 2015.
The meeting will take place in C5320
room 6, U.S. Department of Labor, 200
Constitution Avenue NW., Washington,
DC 20210. Public access is available
only in this room (i.e. not by telephone).
The meeting will run from 9:00 a.m. to
approximately 4:00 p.m. The purpose of
the open meeting is to discuss reports/
recommendations for the Secretary of
Labor on the issues of (1) Model Notices
and Plan Sponsor Education on Lifetime
Plan Participation and (2) Model
Notices and Disclosures for Pension
Risk Transfers. Descriptions of these
topics are available on the Advisory
Council page of the EBSA Web site at
https://www.dol.gov/ebsa/aboutebsa/
erisa_advisory_council.html.
Organizations or members of the
public wishing to submit a written
statement may do so by submitting 30
copies on or before September 23, 2015
to Larry Good, Executive Secretary,
ERISA Advisory Council, U.S.
Department of Labor, Suite N–5623, 200
Constitution Avenue NW., Washington,
DC 20210. Statements also may be
submitted as email attachments in rich
text, Word, or pdf format transmitted to
good.larry@dol.gov. It is requested that
statements not be included in the body
of an email. Statements deemed relevant
by the Advisory Council and received
on or before September 23 will be
included in the record of the meeting
and will be available to anyone by
contacting the EBSA Public Disclosure
Room. Do not include any personally
identifiable information (such as name,
address, or other contact information) or
VerDate Sep<11>2014
14:19 Sep 08, 2015
Jkt 235001
confidential business information that
you do not want publicly disclosed.
Individuals or representatives of
organizations wishing to address the
Advisory Council should forward their
requests to the Executive Secretary or
telephone (202) 693–8668. Oral
presentations will be limited to ten
minutes, time permitting, but an
extended statement may be submitted
for the record. Individuals with
disabilities who need special
accommodations should contact the
Executive Secretary by September 23,
2015 at the address indicated.
Signed at Washington, DC, this 2nd day of
September, 2015.
Judith Mares,
Deputy Assistant Secretary, Employee
Benefits Security Administration.
[FR Doc. 2015–22643 Filed 9–8–15; 8:45 am]
BILLING CODE 4510–29–P
NATIONAL SCIENCE FOUNDATION
National Science Board; Sunshine Act
Meetings; Notice
The National Science Board’s ad hoc
Task Force on NEON Performance and
Plans, pursuant to NSF regulations (45
CFR part 614), the National Science
Foundation Act, as amended (42 U.S.C.
1862n–5), and the Government in the
Sunshine Act (5 U.S.C. 552b), hereby
gives notice in regard to the scheduling
of a meeting for the transaction of
National Science Board business, as
follows:
Friday, September 4,
2015 at 4–5 p.m. EDT.
TIME AND DATE:
This meeting will be held by
teleconference originating at the
National Science Board Office, National
Science Foundation, 4201 Wilson Blvd.,
Arlington, VA 22230.
PLACE:
STATUS:
Closed.
Task Force
Chair’s opening remarks; review and
discussion of the Task Force charge, and
discussion of the status of the NEON
project.
MATTERS TO BE CONSIDERED:
CONTACT PERSON FOR MORE INFORMATION:
Please refer to the National Science
Board Web site (www.nsf.gov/nsb) for
information or schedule updates, or
contact: John Veysey (jveysey@nsf.gov),
National Science Foundation, 4201
Wilson Blvd., Arlington, VA 22230.
Nadene Kennedy,
Polar Coordination Specialist.
[FR Doc. 2015–22727 Filed 9–4–15; 11:15 am]
BILLING CODE 7555–01–P
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
OFFICE OF PERSONNEL
MANAGEMENT
Submission for Review:
Representative Payee Application, RI
20–007 and Information Necessary for
a Competency Determination, RI 30–3,
3206–0140
U.S. Office of Personnel
Management.
ACTION: 60-Day notice and request for
comments.
AGENCY:
The Retirement Services,
Office of Personnel Management (OPM)
offers the general public and other
Federal agencies the opportunity to
comment on a revised information
collection request (ICR) 3206–0140,
Representative Payee Application, RI
20–7; Information necessary for a
competency determination, collects
medical information regarding the
annuitant’s competency in evaluating
the annuitant’s condition, RI 30–3. As
required by the Paperwork Reduction
Act of 1995 (Pub. Law 104–13, 44 U.S.C.
chapter 35) as amended by the ClingerCohen Act (Pub. L. 104–106), OPM is
soliciting comments for this collection.
DATES: Comments are encouraged and
will be accepted until November 9,
2015. This process is conducted in
accordance with 5 CFR 1320.1.
ADDRESSES: Interested persons are
invited to submit written comments on
the proposed information collection to
Retirement Services, U.S. Office of
Personnel Management, 1900 E Street
NW., Washington, DC 20415, Attention:
Alberta Butler, Room 2349, or sent via
electronic mail to Alberta.Butler@
opm.gov.
FOR FURTHER INFORMATION CONTACT: A
copy of this ICR, with applicable
supporting documentation, may be
obtained by contacting the Retirement
Services Publications Team, Office of
Personnel Management, 1900 E Street
NW., Room 3316–AC, Washington, DC
20415, Attention: Cyrus S. Benson or
sent via electronic mail to
Cyrus.Benson@opm.gov or faxed to
(202) 606–0910.
SUPPLEMENTARY INFORMATION:
The Office of Management and Budget
is particularly interested in comments
that:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of functions
of OPM, including whether the
information will have practical utility;
2. Evaluate the accuracy of OPM’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used;
SUMMARY:
E:\FR\FM\09SEN1.SGM
09SEN1
]]>Agencies
[Federal Register Volume 80, Number 174 (Wednesday, September 9, 2015)]
[Notices]
[Pages 54327-54328]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-22626]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: PCAS-Nanosyn,
LLC
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: PCAS-Nanosyn, LLC applied to be registered as a manufacturer
of certain basic classes of controlled substances. The Drug Enforcement
Administration (DEA) grants PCAS-Nanosyn, LLC registration as a
manufacturer of those controlled substances.
SUPPLEMENTARY INFORMATION:
By notice dated May 15, 2015, and published in the Federal Register
on May 21, 2015, 80 FR 29336, PCAS-Nanosyn, LLC, 3331-B Industrial
Drive, Santa Rosa, California 95403 applied to be registered as a
manufacturer of certain basic classes of controlled substances. No
comments or objections were submitted for this notice.
The DEA has considered the factors in 21 U.S.C. 823(a) and
determined that the registration of PCAS-Nanosyn, LLC to manufacture
the basic classes of controlled substances is consistent with the
public interest and with United States obligations under international
treaties, conventions, or protocols in effect on May 1, 1971. The DEA
investigated the company's maintenance of effective controls against
diversion by inspecting and testing the company's physical security
systems, verifying the company's compliance with state and local laws,
and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Oxycodone (9143)........................... II
Oripavine (9330)........................... II
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company is a contract manufacturer. At the request of the
company's customers, it manufacturers
[[Page 54328]]
derivatives of controlled substances in bulk form.
Dated: September 1, 2015
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-22626 Filed 9-8-15; 8:45 am]
BILLING CODE 4410-09-P
